WHO ICTRP trial
Safety, tolerability, and antibody response after intradermal vaccination of…
TCTR20211023002 · Thai Clinical Trials Registry (TCTR) · Not Recruiting
Key facts
| Trial ID | TCTR20211023002 |
|---|---|
| Public title | Safety, tolerability, and antibody response after intradermal vaccination of COVID-19 vaccine; PFE-BNT in adults who have completed two-doses of Verocell (inactivated vaccine) |
| Scientific title | Safety, tolerability, and antibody response after intradermal vaccination of COVID-19 vaccine; PFE-BNT in adults who have completed two-doses of Verocell (inactivated vaccine) |
| Primary sponsor | Lampang Hospital |
| Registry | Thai Clinical Trials Registry (TCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | Thailand |
| Conditions | Local reactions and systemic reactions after ID injection of PFE-BNT , antibody response after ID injection of PFE-BNT immunogenicity side effects;immunogenicity side effects |
| Interventions | PFE-BNT was prepared under the recommendation of department of disease control, Thailand. Sterile 0.9% of Nacl 1.8 ml is added into PFE-BNT vaccine vial as a diluent. After diluting, each vial contains 6 doses of vaccine, each IM injection… |
| Registration date | Oct 23, 2021 |
| Target size | 40 |
| Secondary IDs | Nil Known |
| Registry page | thaiclinicaltrials.org |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: